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Immunoglobulin G4-related systemic disease (IgG4-RSD) is a recently defined 
emerging entity characterized by a diffuse or mass forming inflammatory reaction 
rich in IgG4-positive plasma cells associated with fibrosclerosis and obliterative 
phlebitis. IgG4-RSD usually affects middle aged and elderly patients, with a male 
predominance. It is associated with an elevated serum titer of IgG4, which acts as a 
marker for this recently characterized entity. The prototype is IgG4-related sclerosing 
pancreatitis or autoimmune pancreatitis (AIP). Other common sites of involvement 
are the hepatobiliary tract, salivary gland, orbit, and lymph node, however practically 
any organ can be involved, including upper aerodigestive tract, lung, aorta, mediasti-
num, retroperitoneum, soft tissue, skin, central nervous system, breast, kidney, and 
prostate. Fever or constitutional symptoms usually do not comprise part of the clini-
cal picture. Laboratory findings detected include raised serum globulin, IgG and 
IgG4. An association with autoantibody detection (such as antinuclear antibodies and 
rheumatoid factor) is seen in some cases. Steroid therapy comprises the mainstay of 
treatment. Disease progression with involvement of multiple organ-sites may be en-
countered in a subset of cases and may follow a relapsing-remitting course. The prin-
cipal histopathologic findings in several extranodal sites include lymphoplasmacytic 
infiltration, lymphoid follicle formation, sclerosis and obliterative phlebitis, along 
with atrophy and destruction of tissues. Immunohistochemical staining shows in-
creased IgG4+ cells in the involved tissues (>50 per high-power field, with IgG4/
IgG ratio >40%). IgG4-RSD may potentially be rarely associated with the develop-
ment of lymphoma and carcinoma. However, the nature and pathogenesis of IgG4-
RSD are yet to be fully elucidated and provide immense scope for further studies.
Key Words:    IgG4-related sclerosing disease, IgG4, autoimmune pancreatitis, scle-
rosing cholangitis, inflammatory fibrosclerosing lesion, inflammatory 
pseudotumor, lymphadenopathy, salivary gland, lacrimal gland
INTRODUCTION
Immunoglobulin subtypes are significantly different in their underlying biologic regu-Mukul Divatia, et al.
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cal entity, characterized by a mass lesion in the pancreas, 
painless obstructive jaundice, pancreatic duct narrowing, 
association with diabetes mellitus and favorable response to 
steroid therapy.
The autoimmune association of AIP is based upon its as-
sociation with other immune-mediated diseases, such as 
sclerosing cholangitis, primary biliary cirrhosis (PBC), Sjo-
gren syndrome, and inflammatory bowel disease (IBD).15,16 
Autoantibodies, including antinuclear antibodies, rheu-
matoid factor, anticarbonic anhydrase II, and antilactofer-
rin are commonly encountered in patients with AIP.17-20 
Kawa, et al.21 reported an association with HLA DRB1 
*0405-DQB1*0401 haplotype in a study from Japan. Nu-
merous terminologies have been coined by different in-
vestigators to emphasize selected aspects of the disease, 
including chronic sclerosing pancreatitis,22 lymphoplas-
macytic sclerosing pancreatitis,23 nonalcoholic duct-de-
structive chronic pancreatitis,24 idiopathic tumefactive 
chronic pancreatitis25 and duct-narrowing chronic pancre-
atitis.26 Over the past decade, developments have resulted 
in the establishment of the theory that AIP is a heteroge-
neous entity which includes at least 2 distinct clinicopatho-
logic entities: 1) lymphoplasmacytic sclerosing pancreatitis 
(LPSP), and 2) idiopathic duct-centric chronic pancreatitis 
(IDCP).19,27,28 
LPSP is a histologically unique lesion that was proposed 
by Kawaguchi, et al.23 in 1991. It consists of diffuse lym-
phoplasmacytic infiltration and fibrosis that focally gives 
rise to a storiform fibrosis. Neutrophils are conspicuously 
absent but eosinophils may be identified. Pancreatic lobules 
are relatively well preserved compared to alcoholic chronic 
pancreatitis, but focal destruction of pancreatic acini and re-
placement with fibrosis are routinely noted. This inflamma-
tory process also characteristically extends around the main 
and interlobular ducts, leaving the duct epithelium and lu-
men intact. Veins are almost always obliterated by the same 
inflammatory process (obliterative phlebitis). Even the 
splenic and portal venous vasculature may be involved, 
leading to an intraoperative differential diagnosis of carci-
noma. The common bile duct is usually inflamed resulting 
in jaundice seen in patients with AIP. Numerous IgG4-posi-
tive plasma cells are identified in LPSP on staining.29,30 
LPSP predominantly affects elderly men with a mean age 
of 62 to 63.4 years, is commonly associated with proximal 
biliary tract, retroperitoneal, renal, and salivary disease, 
shows elevated serum IgG4 titer and  relapse (47%) in a 
significant proportion of cases.31
lation, distribution, and in their interaction with receptors 
on the various effector cells of the immune system. The im-
munoglobulin subtypes that are produced in response to a 
particular immune challenge depend on class-switch gene 
rearrangement of the constant regions.1 The immunoglobu-
lin G (IgG) class is complex in structure and biology with 
four subclasses of IgG antibodies, ranging from 1 through 4 
based upon the order of their discovery and serum levels. 
The serum concentration of IgG1 is the highest amongst 
the IgG subclasses and ranges from 5-11 mg/mL,2 whereas 
the least abundant subclass, IgG4, is present at mean con-
centrations of 0.35-0.51 mg/mL.3 The concentration of IgG4 
in serum varies significantly among healthy people unlike 
the other IgG subclasses. IgG4 levels generally range from 
less than 10 μg/mL to 1.4 mg/mL, with levels over 2 mg/
mL noted in rare instances and levels being generally high-
er in men and older people.2-4
IgG4 is a unique antibody based upon its structure, func-
tion, and immunologic regulation. IgG4 antibodies are dis-
tinct as they undergo ‘half-antibody exchange’ in vivo, re-
sulting in recombined antibodies comprising two different 
binding specificities.5 IgG4 does not activate complement 
pathways and has reduced effector function relative to other 
IgG subtypes.6,7 IgG4 production is driven in part by T- 
helper cell 2 cytokines.8,9 IgG4 plays a significant role in 
bullous skin lesions,10 atopic eczema and bronchial asth-
ma11,12 as well as decreasing IgE-mediated inflammatory re-
sponse in parasitic infections.8,9 IgG4-related systemic dis-
ease (IgG4-RSD) represents a newly described category of 
diseases with a potential role for IgG4 antibodies. The exact 
role of IgG4 antibodies in the pathogenesis of IgG4-RSD 
still remains unclear in the present day scenario. An in-
creased understanding of the precise role of IgG4 in these 
related clinical syndromes will be paramount for elucida-
tion of the underlying pathophysiology.
HISTORICAL PERSPECTIVE OF 
AUTOIMMUNE PANCREATITIS AND 
IgG4-RELATED DISEASES
 
Sarles, et al.13 raised the possibility of some cases of chron-
ic pancreatitis arising from an autoimmune pathologic pro-
cess in 1961. The concept of autoimmune pancreatitis 
(AIP) was proposed by Yoshida, et al.14 in 1995 along with 
the introduction of this terminology. Autoimmune pancre-
atitis has been recognized over the years as a distinct clini- IgG4-Related Sclerosing Disease 
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IgG4-RELATED SCLEROSING 
PANCREATITIS
In 2001, Hamano, et al.40 reported elevated serum IgG4 lev-
els in a cohort of patients with a specific subtype of sclerosing 
pancreatitis/AIP. This finding was not observed in patients 
with pancreatic carcinoma, primary sclerosing cholangitis 
(PSC), PBC, nonspecific chronic pancreatitis, Sjogren syn-
drome and normal subjects. Kamisawa, et al.41 reported that 
IgG4-positive plasma cells are increased systemically in 
patients with AIP and concluded that AIP patients have a 
systemic disease, with the proposal for the entity ‘IgG4-re-
lated sclerosing disease’.42 Histologically, this subtype cor-
responds to LPSP, but not IDCP.30,32,43
CLINICAL FEATURES OF IgG4-
RELATED SCLEROSING PANCREATITIS
 
IgG4-related sclerosing pancreatitis is seen most commonly 
in middle-aged and elderly men with a mean age of 59 to 68 
years and a male-to-female ratio of 4-7.5: 1.44-46 The preva-
lence rate is 2% to 11% among patients with chronic pancre-
atitis.20,45 Studies have demonstrated that it accounts for up to 
one third of the total cases of benign conditions that are treat-
ed with pancreatoduodenectomies, thus highlighting the fact 
that is often mistaken for pancreatic cancer in spite of major 
advancements in clinical medicine and radiology.47,48
Patients usually present with a pancreatic mass and/or 
painless obstructive jaundice. Newly diagnosed type II dia-
betes mellitus and steatorrhea are noted in some of these cas-
es.20,37 Contrarily, systemic symptoms, including fever, 
weight loss, and generalized malaise are rarely seen. Imag-
ing studies characteristically show enlargement of the pan-
creas, predominantly involving the pancreatic head, and en-
doscopic retrograde cholangiopancreatography (ERCP) 
shows irregular narrowing of the pancreatic duct with or 
without stenosis of the common bile duct.36
The disease responds well to steroid therapy, although re-
lapses can occur on cessation of treatment.37 Response to 
treatment is monitored by a decline in serum IgG4 titer and 
a reduction in IgG4+ cells in the affected organs. Ritux-
imab administration may be significantly beneficial accord-
ing to a recent study which reports an excellent response in 
IgG4-related pancreatitis cases.49 The drug acts by reducing 
the number of B-lymphocytes that provide a source for the 
IDCP is characterized by ductal epithelium centric in-
flammation.16,27,32 Neutrophilic infiltration in the main and/
or interlobular ducts is typically seen, and extends to in-
volve the duct epithelium and lumen. The duct epithelium 
shows destructive and regenerative changes with the lu-
men appearing stenotic or tortuous as a result of the in-
flammation. A band of lymphocytes and plasma cells sur-
rounds the lumen but, in contrast to LPSP, the ductal 
lesion lacks the appearance of a thickened wall. The entire 
duct may seem entrapped within an aggregate of inflam-
matory cells. When the inflammation is severe, pancreatic 
lobules are also inflamed with neutrophils, lymphocytes 
and plasma cells and microabscesses may be seen as well. 
Although there is fibrosis around pancreatic lobules, in-
flammatory cells are scarce within fibrosis itself, in con-
trast to LPSP, in which inflammatory cells are numerous 
within fibrosis. Obliterative phlebitis is rare, and inflam-
mation of the common bile duct is less common com-
pared to LPSP. IgG4-positive plasma cells are usually few 
in IDCP.32
The clinical features of LPSP are concordant with those 
of AIP reported from Japan, described previously.27 Serum 
IgG4 is elevated in 80% of AIP patients in Japan, which 
correlates well with numerous IgG4-positive plasma cells 
seen in LPSP. In contrast, patients with IDCP are younger 
than LPSP patients, and many of them are younger than 40 
years without any specific gender preponderance.27 Ob-
structive jaundice is less common in IDCP than in LPSP. 
The association of IBD is found in IDCP, but extrapancre-
atic manifestations seen in LPSP are rare. It is noteworthy 
that IDCP is rare in Japan.33
Owing to the fact that both LPSP and IDCP have over-
lapping clinicopathological features, there has been a con-
tentious debate as to whether these two pathological 
groups are different manifestations of a single entity of 
AIP, or whether they are distinct clinicopathological enti-
ties. The controversy is due to the variety of AIP diagnos-
tic criteria proposed by different groups. The diagnostic 
criteria from Japan,34 Korea,35 consensus of the Japan-Ko-
rea symposium36 and Mayo Clinic37 define LPSP as the 
pathological entity of AIP, but other groups include both 
LPSP and IDCP in AIP.16,32,38 The theory that LPSP and 
IDCP are distinct entities has gained acceptance due to the 
differing demographic and clinical presentations as well as 
different immunoreactivity for IgG4. Recently, new no-
menclature, type 1 and type 2 AIP, which correspond to 
LPSP and IDCP, respectively, have been proposed.39Mukul Divatia, et al.
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sclerosis, and 3) obliterative phlebitis, with accompanying at-
rophy and destruction of pancreatic acini although these mor-
phologic features are characteristic, they are not completely 
specific, and thus a definitive diagnosis requires the demon-
stration of an increased population of IgG4+ plasma cells.31
Sclerosis of the interlobular septa further enhances the 
lobular architecture of the pancreas by making the separate 
lobules appear more demarcated (Fig. 2A). The extent of 
involvement varies greatly from one lobule to another. This 
may range from normal appearing lobules, to moderate at-
rophy and inflammation, and complete replacement by a fi-
broinflammatory process. The pancreatic lobules show in-
terstitial infiltration by plasma cells, reactive lymphocytes, 
and a variable number of eosinophils, accompanied by atro-
phy or loss of acini (Fig. 2B). The lobular stroma shows vari-
able degrees of sclerosis, which can exhibit a storiform char-
acter.36,37 Prominent edema or myxoid change may be noted. 
Increasing degrees of sclerosis results in loss of the lobular 
architecture.50 The fibrosclerosis and inflammatory process 
can extend beyond the confines of the pancreas into the ret-
roperitoneal tissue and surrounding organs. Islet cell hyper-
plasia is a rare finding in contradistinction to the routinely 
encountered examples of chronic pancreatitis. The pancre-
IgG4- secreting plasma cells. 
MORPHOLOGIC FEATURES OF IgG4-
RELATED SCLEROSING PANCREATITIS
The cut surface of the pancreas is firm with tan-white areas 
interspersed amidst the lobulated yellow-gray parenchyma 
(Fig. 1). The histologic triad necessary for a diagnosis com-
prises of the following: 1) lymphoplasmacytic infiltrate, 2) 
Fig. 1. The gross photograph of pancreas shows an ill-defined firm lesion in 
the head of the pancreas (arrow) with yellow-tan and fibrotic cut surface. 
The lesion extends into the peripancreatic fat tissue. 
Fig. 2. Microscopic features of IgG4-related sclerosing pancreatitis. (A) Pancreatic lobules are replaced by severe inflammatory cell infil-
tration and fibrosis. Sclerosis of interlobular septa enhances lobular architecture of pancreas (H&E stain, original magnification ×40). (B) 
The lobular interstitium is infiltrated by plasma cells, lymphocytes, and a variable number of eosinophils. Residual atrophic pancreatic 
acini are identified (right upper corner, arrow; H&E stain, original magnification ×400). (C) Obliterative phlebitis is characterized by peri-
venular and intravenular inflammatory cell infiltrate with fibrous obliteration of the lumen (H&E stain, original magnification ×200). (D) 
IgG4 immunostain shows markedly increased IgG4-positive plasma cells (>50 plasma cells/HPF; immunohistochemical stain, original 
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(Fig. 2D).53 In nonspecific chronic inflammation or pancre-
atic carcinoma, few scattered IgG4+ cells are seen. The 
number of IgG4+ plasma cells is more sensitive and specif-
ic than serum IgG4 titer as the latter is not elevated in ap-
proximately one third of cases but may be elevated in other 
conditions such as in patients with pancreatic carcino-
ma.54-56 Alternatively, the ratio of IgG4+/IgG+ cells (>40%)   
can be used as a standard parameter to arrive at a sensitive 
and specific diagnosis.43,57,58
The diagnosis of IgG4-related sclerosing pancreatitis is 
usually rendered upon consideration of clinical, laboratory, 
imaging, and histologic features. Biopsies may be falsely 
negative since the pancreas may not be involved in its en-
tirety.59 ERCP guided biopsies of the pancreas may be more 
helpful in demonstrating the presence of IgG4+ plasma 
cells.60 The diagnostic criteria have undergone several chang-
es and vary from one continent to another (Table 1 and 2). 
However, the diagnosis is almost always determined by the 
discovery of increased number of IgG4-positive plasma 
cells coupled with the morphologic findings. The diagnosis 
can be rendered possible in the absence of biopsy tissue 
with the aid of imaging studies, extrapancreatic organ in-
volvement, and response to steroids may help in establish-
ing the diagnosis if tissue samples are not available.36,37,61
IgG4-related sclerosing pancreatitis is frequently associat-
ed with extrapancreatic lesions, and the spectrum of disease 
manifestations involving different organs has continued to 
expand.20,37,61-72 Hamano, et al.62 reported that extrapancreatic 
bile duct lesions occur in 73.9%, hilar lymphadenopathy 
occurs in 80.4%, lacrimal and salivary gland lesions in 
atic ducts appear more prominent as a result of being sur-
rounded by a periductal cuff of chronic inflammatory cells, 
accompanied by a sclerosing stromal reaction. The ductal 
epithelium is not infiltrated by inflammatory cells. Irregular 
narrowing of the ductal lumen gives rise to the characteris-
tic imaging findings. 
Phlebitis, characterized by transmural inflammatory infil-
tration of the veins, with or without fibrous obliteration of 
the lumen, is a sine qua non of this disease (Fig. 2C).31 An 
elastic stain may highlight the venous obliteration. Lymphoid 
follicles can be present in the stroma. Sometimes fibroin-
flammatory mass lesions are formed, which have been called 
“inflammatory pseudotumor” in the literature.51 Another 
noteworthy feature often not reported is the tendency for 
the inflammatory cells to form cuffs around nerves. Plasma 
cells and lymphocytes can even infiltrate into the nerves.31
DIAGNOSIS OF IgG4-RELATED 
SCLEROSING PANCREATITIS AND 
IgG4-RELATED SCLEROSING DISEASE
A preoperative diagnosis of IgG4-related sclerosing pancre-
atitis is necessitated by the need to avoid surgery in these 
cases which are otherwise treated with steroids.52 Although 
there is no definite cut-off limit for the number of IgG4+ 
plasma cells currently, greater than 30 IgG4+ plasma cells 
per high-power field has been reported as being specific.30,32 
A recent study suggests a cut-off level of more than 50 per 
high-power field IgG4-positive cells to be more specific 
Table 1. Asian Diagnostic Criteria (Japan-Korea Consensus) for Autoimmune Pancreatitis (IgG4-related Scle-
rosing Pancreatitis)
Criterion I-Imaging (both required)
1. Pancreatic parenchyma-diffuse/segmental/focal enlargement of the gland, 
    occasionally with a mass and/or hypoattenuation rim
2. Pancreaticobiliary ducts-diffuse/segmental/focal pancreatic duct narrowing, 
    often with stenosis of bile duct
Criterion II-Serology (1 required) 1. High levels of serum IgG or IgG4
2. Detection of autoantibodies
Criterion III-Histopathology of 
  pancreatic biopsy Lymphoplasmacytic infiltration with fibrosis and abundant IgG4+ cells
Criterion IV-Histopathology of 
  resected pancreas
Lymphoplasmacytic sclerosing pancreatitis 
  (storiform fibrosis, lymphoplasmacytic infiltration, periductal inflammation, 
  obliterative phlebitis, numerous IgG4+ cells)
Optional criterion-Response to 
  steroid therapy
Diagnostic trial of steroid therapy should be conducted only in patients fulfilling 
  criterion I alone with negative work-up results for pancreatobiliary cancer
Diagnostic of autoimmune 
  pancreatitis when any of the 
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association of “autoimmune pancreatitis” with other “auto-
immune diseases” including PSC, Sjogren syndrome, and 
retroperitoneal fibrosis simply represents extrapancreatic 
manifestations of a single systemic entity rather than a mul-
titude of diseases.39,73,74 Another pointer favoring this theory 
states that an increased number of IgG4+ plasma cells can 
be identified in other uninvolved organs in such cases or-
gans, such as the aerodigestive tract mucosa and bone mar-
39.1%, hypothyroidism in 22.2%, and retroperitoneal fibro-
sis in 12.5% of cases with IgG4-RSD. The various sites of 
involvement exhibit similar morphologic features with the 
common denominator being a significant increase in the 
number of IgG4+ plasma cells (Table 3).29,41,42
Extrapancreatic involvement may develop prior to, con-
comitantly or following pancreatic disease, or may even oc-
cur independently in the absence of pancreatitis. A so called 
Table 2. Mayo Clinic Diagnostic Criteria for Autoimmune Pancreatitis (IgG4-related Sclerosing Pancreatitis): 
The HISORt Criteria
Criterion H-Histology 
  (at least one of the following)
1. Periductal lymphoplasmacytic infiltrate, obliterative phlebitis, 
    storiform fibrosis
2. Lymphoplasmacytic infiltrate, storiform fibrosis, abundant 
    IgG4+ cells (≥10 HPF)
Criterion I-Imaging of pancreas
1. Typical-diffusely enlarged gland with delayed (rim) enhancement; 
    diffusely irregular, attenuated main pancreatic duct
2. Others-Focal pancreatic mass/enlargement; focal pancreatic duct 
    stricture; pancreatic atrophy; pancreatic calcification; pancreatitis
Criterion S-Serology Elevated serum IgG4 (normal: 8-140 mg/dL)
Criterion O-Other organ involvement 
  (can be confirmed by biopsy or resolution/
  improvement with steroid therapy)
Hilar/intrahepatic biliary strictures; persistent distal biliary stricture; 
  parotid/lacrimal gland involvement; mediastinal lymphadenopathy; 
  retroperitoneal fibrosis
Criterion R-Response to steroid therapy Resolution or marked improvement of pancreatic/extrapancreatic 
  manifestation with steroid therapy
Diagnostic of autoimmune pancreatitis when 
  any of the following is fulfilled
1. Criterion H
2. Criterion I+S
3. Strong clinical suspicion of autoimmune pancreatitis 
    (idiopathic pancreatic disease+Criterion S and/or O)+Criterion R
IgG4, immunoglobulin G4; HPF, high-power fields.
Table 3. Body Sites Affected by IgG4-Related Sclerosing Disease
Body site Clinicopathologic features
Pancreas Lymphoplasmacytic sclerosing pancreatitis (type 1 AIP) and idiopathic duct centric  
  chronic pancreatitis (type 2 AIP)
Bile duct Sclerosing cholangitis
Gall bladder Acalculous sclerosing cholecystitis
Liver
Sclerosing cholangitis involving intrahepatic ducts, inflammatory pseudotumor, portal 
  inflammation with or without interface hepatitis, portal sclerosis, large bile duct 
  obstruction, lobular hepatitis, canalicular cholestasis 
Salivary glands Chronic sclerosing sialadenitis (Kuttner tumor), Mikulicz disease
Lacrimal glands and orbit Chronic sclerosing dacryoadenitis, inflammatory pseudotumor
Retroperitoneum and  
  mesentery Retroperitoneal fibrosis, sclerosing mesenteritis
Cardiovascular/Aorta  Inflammatory abdominal aortic aneurysm
Mediastinum  Sclerosing mediastinitis
Kidney and ureter Tubulointerstitial nephritis, membranous glomerulopathy, inflammatory pseudotumor
Thyroid  Hypothyroidism, Riedel’s thyroiditis
Breast  Sclerosing mastitis
Lung Inflammatory pseudotumor, interstitial pneumonia
Central nervous system Hypophysitis, sclerosing pachymeningitis
Prostate Prostatitis
Lymph node Lymphadenopathy with Castleman disease like features, follicular hyperplasia, 
  interfollicular expansion by plasma cells and immunoblasts IgG4-Related Sclerosing Disease 
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ferential diagnoses are nonspecific inflammation with 
fibrosis, and malignancies with sclerosis including nodular 
sclerosing Hodgkin lymphoma, sclerosing large B-cell 
lymphoma, primary or metastatic carcinoma with desmo-
plastic stromal changes. The veins show segmental or cir-
cumferential transmural infiltration by chronic inflammato-
ry cells, and can show luminal occlusion by fibrous tissue.31 
Obliterated veins can be difficult to recognize and may ne-
cessitate the aid of elastin stains for identification purposes.
Hepatobiliary system
Biliary tract involvement (IgG4-related sclerosing cholan-
gitis) is seen in 50% to 90% of patients with IgG4-related 
sclerosing pancreatitis and clinically presents as obstructive 
jaundice or fever.23,51,81-84 Biliary tract disease may also be 
seen in some cases without pancreatic involvement. Both 
the extrahepatic and intrahepatic bile duct systems can be 
affected with the prior being predominantly involved in 
most reported cases.85 As seen with AIP, the differential di-
agnosis includes a malignancy of the bile duct system.81-85 
The involved bile ducts demonstrate a transmural lympho-
plasmacytic infiltrate with variable numbers of eosinophils, 
sclerosis (Fig. 3A), and obliterative phlebitis (Fig. 3B).  The 
bile duct lumina undergo stenosis owing to the periductal 
fibrosis and inflammation (Fig. 3C) and the peribiliary 
glands are often involved in this region.85 Immunohisto-
chemical staining for IgG4 demonstrates a significant sub-
set as being IgG4-positive plasma cells (Fig. 3D). 
The clinical and pathologic features overlap with those 
seen in PSC, a chronic biliary inflammatory disease of un-
known etiology. The pathologic process in PSC also involves 
prominent ductal and periductal fibrosis, luminal stenosis, 
obliteration, and dilatation.86 It is thought that some of the 
cases reported as PSC actually represent IgG4-related scle-
rosing cholangitis.87-91 Mendes, et al.92 published a series of 
cases of PSC wherein elevated serum IgG4 was found in 
9% of the patients and this group of patients also had a low-
er frequency of IBD.
In IgG4-RSD involving the bile ducts, the bile duct epi-
thelium is usually spared but the peribiliary glands exhibit a 
greater degree of involvement and inflammation tends to be 
more severe toward the adventitial aspect. Onion-skin type 
concentric periductal fibrosis, which is a diagnostic hall-
mark of PSC, is not seen in IgG4-related cholangitis.81-84 
Another distinguishing feature is that a large number of 
IgG4-positive plasma cells are identified in IgG4-related 
cholangitis but not in PSC. PSC is a progressive disease 
row, thus providing credence in favor of the systemic na-
ture of this disease.42,65,75,76 The various names ascribed to 
this disease include IgG4-related sclerosing disease,77 IgG4-
related systemic sclerosing disease,78 IgG4-related dis-
ease,61,79 IgG4-related autoimmune disease,42 hyper-IgG4 
disease,80 and IgG4-related systemic disease.49 
The extrapancreatic lesions of IgG4-related sclerosing 
disease also exhibit the same characteristic histologic fea-
tures including lymphoplasmacytic infiltrate, sclerosis, and 
obliterative phlebitis as similarly seen in IgG4-related scle-
rosing pancreatitis. The relative proportion of the lympho-
plasmacytic infiltrate and sclerosis in different cases gives 
rise to a spectrum of histologic patterns: pseudolymphoma-
tous, mixed, and sclerosing. These patterns represent differ-
ent stages in the evolution of this disease with the sequence 
progressing from being initially pseudolymphomatous to 
mixed and subsequent progression to the sclerosing pattern. 
The pseudolymphomatous pattern is more commonly iden-
tified in superficial locations including lacrimal gland, sali-
vary gland, breast, and skin and thus these are detected ear-
lier than deep seated sclerotic lesions in locations such as 
the retroperitoneum.31
The pseudolymphomatous pattern is characterized by a 
mass forming dense infiltrate of small lymphocytes and 
plasma cells, with interspersed reactive lymphoid follicles 
and a variable proportion of scattered eosinophils. The dif-
ferential diagnosis includes low grade non-Hodgkin’s lym-
phoma, particularly extranodal marginal zone lymphoma. 
However, these can be distinguished based on the absence 
of lymphoepithelial lesions, monocytoid B-cells, diffuse 
sheets of CD20+ B cells, light chain restriction, aberrant 
immunophenotype, and clonal immunoglobulin gene rear-
rangements.31
The mixed pattern is the most common, comprising of 
patchy dense infiltrates of small lymphocytes and plasma 
cells that are accompanied by significant sclerosis (Fig. 
2B). Variable numbers of eosinophils and reactive lym-
phoid follicles are usually seen. The sclerosing pattern is 
characterized by a predominantly sclerotic process with 
poorly defined borders and irregular extensions into the sur-
rounding tissues. Patchy aggregates of lymphocytes and 
plasma cells, with or without lymphoid follicle formation, 
are seen diffusely scattered over the extent of the lesion, 
and are seen more commonly at the periphery than at the 
center of the lesion. The sclerotic areas comprise of colla-
gen deposition with scattered fibroblasts.  Obliterative phle-
bitis is often seen except in small biopsies.31 The main dif-Mukul Divatia, et al.
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patic tissue.31,51,96,97
This IgG4-related lesion is morphologically different 
from soft tissue related lesions including inflammatory 
pseudotumor/inflammatory myofibroblastic tumor of the 
liver since it does not comprise of a spindle cell or myofi-
broblastic proliferation, does not express the ALK protein 
frequently associated with inflammatory myofibroblastic 
tumor and instead comprises of numerous IgG4+ plasma 
cells with surrounding sclerosis and phlebitis.98 Follicular 
dendritic cell sarcoma is another entity which must be in-
cluded in the differential diagnosis of these lesions but can 
be distinguished by the presence of intersecting fascicles of 
spindle cells as well as positivity for follicular dendritic cell 
markers (CD21 and CD35), and Epstein-Barr virus in situ 
hybridization studies.31,99
Different morphologic patterns are appreciated in liver 
biopsies obtained from patients with IgG4-RSD. These in-
clude portal inflammation with or without interface hepati-
tis, portal sclerosis, large bile-duct obstructive features, lob-
ular hepatitis, and canalicular cholestasis.100 The number of 
IgG4+ plasma cells is concomitantly increased and helps to 
distinguish IgG4-related hepatic disease from other differ-
culminating in cirrhosis with liver failure requiring trans-
plantation, whereas IgG4-related sclerosing cholangitis is 
treated with steroid therapy in most  cases.81-84,93
The gall bladder may be involved  in up to one fourth of 
patients with IgG4-related sclerosing pancreatitis with the 
most common manifestation being acute acalculous chole-
cystitis.94 Co-existing IgG4-related sclerosing cholangitis is 
also frequently encountered. IgG4-related cholecystitis shows 
predominant extramural involvement with adventitial in-
flammation and subserosal inflammatory nodules in con-
trast to the nonspecific acalculous cholecystitis, which is 
seen occasionally in patients with PSC, pancreatic cancer, 
and biliary calculi.58,95 
Hepatic involvement is also frequently identified with 
IgG4-related cholangitis or pancreatitis. The commonest 
presentation is seen as a mass lesion often referred to as an 
“inflammatory pseudotumor”.51,96,97 The lesion usually in-
volves the hilum of the liver and is bile duct centric with 
the usual diagnostic triad of a lymphoplasmacytic infiltrate, 
sclerosis, and obliterative phlebitis. IgG4-related hepatic 
“inflammatory pseudotumor” might represent an extension 
of IgG4-related sclerosing cholangitis into surrounding he-
Fig. 3. Microscopic features of IgG4-related sclerosing cholangitis. (A) Intrahepatic bile ducts are infiltrated by lymphoplasmacytes with 
variable numbers of eosinophils, intermixed with collagen fibers (H&E stain, original magnification ×400). (B) Lymphoplasmacytes are in-
filtrating in the perivenular soft tissue of large veins, resulting in vascular wall destruction and luminal obliteration (H&E stain, original 
magnification ×200). (C) The bile duct lumen undergoes stenosis due to the periductal fibrosis and inflammation (H&E stain, original mag-
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junctivitis sicca, xerostomia, intermittent swelling of the 
salivary or lacrimal glands, presence of anti-Ro/SSA and 
anti-La/SSB autoantibodies, and morphologically charac-
terized by lymphoepithelial sialadenitis.110
Orbit, including lacrimal glands
IgG4-RSD commonly affects the lacrimal glands and sur-
rounding orbital soft tissues and these were the initial sites 
reported to be involved by this disease apart from the pan-
creas. The patients usually present with unilateral or bilater-
al, painless orbital swellings of long duration with or with-
out significant impairment of visual acuity or symptoms of 
‘dry eye’.60,65 The differential diagnosis on clinical and ra-
diological examination includes inflammatory pseudotumor 
and lymphoma. Extensive involvement of orbital soft tissues 
and sclerosis may lead to markedly decreased visual acuity 
and occasionally cause optic nerve atrophy and blindness.65 
Steroid therapy is the primary treatment but may fail to 
ameliorate the condition in severe cases with irreversible 
sclerosis and fibrosis of orbital tissues.60,65 
The morphologic features of lacrimal gland involvement 
(IgG4-related chronic sclerosing dacryoadenitis) are similar 
to those of IgG4-related sclerosing disease in other organs, 
except that obliterative phlebitis is not as commonly seen.60,65 
Progressive sclerosis and gland destruction frequently com-
prise the course of this disease in the orbit with an eventual 
burnout phase where only the fibrosis remains in the ab-
sence of increased inflammation. It may cause extensive fi-
brosis to the degree that no recognizable lacrimal gland or 
orbital structure is identified on biopsies. All patterns of in-
flammation and fibrosis, including pseudolymphomatous, 
mixed and sclerotic patterns, are identified in the lacrimal 
gland and orbital tissues.31,60,65
Retroperitoneum and mesentery, mediastinum, and 
aorta
Inflammatory fibrosclerosing lesion involving the retroperi-
toneum, mesentery and mediastinum is an idiopathic entity 
characterized by diffuse fibrosis and is confused with in-
flammatory pseudotumor or inflammatory myofibroblastic 
tumor.111 Idiopathic retroperitoneal fibrosis or mediastinal fi-
brosis may be associated with Riedel thyroiditis, orbital/lac-
rimal IgG4-RSD or IgG4-related sclerosing cholangitis.112 
The fibrosis in these locations may extend to involve the 
kidney, ureter and bowel mesentery with varying response 
to steroid therapy which is ineffective in advanced fibro-
sis.113-118
entials including PSC, autoimmune hepatitis, primary bili-
ary sclerosis, and chronic viral hepatitis in which only far 
fewer IgG4+ plasma cells are identified.100,101
Salivary gland
The submandibular gland is the salivary gland most fre-
quently involved by IgG4-RSD and is also referred to as 
‘chronic sclerosing sialadenitis’ or ‘Kuttner tumor’. The 
disease was originally described by H. Kuttner102 in 1896, 
who reported it as a unilateral or bilateral ‘‘hard swelling’’ 
of the submandibular glands. Chronic sclerosing sialadeni-
tis demonstrates a predilection for the submandibular gland, 
although parotid gland involvement has also been report-
ed.103 It is characterized by the presence of a prominent 
lymphoplasmacytic infiltrate and lymphoid follicles, which 
upon being combined with the finding of cytotoxic T cell 
populations, indicate an immunological process.104 
Clinical manifestations include unilateral or bilateral hard 
masses that are often mistaken for a tumor based on both 
clinical and radiological features.57,61,64,105-107 Almost all cas-
es of chronic sclerosing sialadenitis have been shown to be 
IgG4-related in the submandibular gland, whereas up to a 
third of all cases of nonspecific chronic sialadenitis are 
IgG4-related.57,61,64 Recognition of IgG4-RSD in the sali-
vary glands is significantly important as these patients may 
develop IgG4-related lesions in other body sites as well. 
The parotid glands can be involved either solely or along 
with the submandibular glands. The morphologic features 
of salivary gland involvement are identical to those ob-
served in other organs.57,61,64 It is characterized by sclerosis 
of interlobular septae with resulting accentuation of the sal-
ivary gland lobular architecture and an interstitial infiltrate 
of lymphocytes and plasma cells along with variable de-
grees of sclerosis. The involvement of adjacent salivary 
lobules may be non-uniform with focal atrophy and loss of 
acini in some lobules. Reactive lymphoid follicles and col-
lagenous sheaths around small ducts are frequently 
seen.57,61,64 
IgG4-related sclerosing dacryoadenitis and/or sialadenitis 
is one of the major causes of Mikulicz disease with bilateral 
lacrimal and salivary glands involvement.108-110 Mickulicz 
disease, which can represent a number of clinical etiologic 
entities, is defined clinically as bilateral, painless, and sym-
metrical swelling of the lacrimal, parotid, and submandibu-
lar glands of unknown etiology for a duration exceeding 3 
months. It is not synonymous with the entity Sjogren syn-
drome, a distinct autoimmune disease featuring keratocon-Mukul Divatia, et al.
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Lung and pleura
Lung involvement by IgG4-RSD may present insidiously 
with the usual pulmonary symptoms including cough, chest 
pain, dyspnea and hemoptysis.69,139-141 Radiologically, it 
may appear as solitary or multiple lung nodules, or consoli-
dation and hilar lymphadenopathy.142 Distinct patterns of   
pulmonary involvement include: solid nodules, peribronchial 
or perivascular, and interstitial alveolar infiltrates.140
The solid nodular type comprises a hilar or peripheral 
mass forming lesion with the characteristic lymphoplasma-
cytic infiltrate and accompanying sclerosis.69 The adjacent 
alveoli show interstitial infiltration of lymphocytes and plas-
ma cells. In cases involving the hilum, sclerosing inflam-
mation of the bronchial wall is identified and it is almost al-
ways accompanied by involvement of the bronchial glands. 
The bronchovascular type is characterized by lymphoplas-
macytic infiltrate distributed along the lymphatic channels, 
with interstitial expansion and extension along the broncho-
vascular bundles, interlobular septa, and pleura. Lymphatic 
dilatation with histiocytes showing emperipolesis of lym-
phocytes is a helpful identifying feature.139 In the alveolar 
interstitial type, the lymphoplasmacytic infiltrate is limited 
to the alveolar interstitium and is difficult to distinguish 
from nonspecific interstitial pneumonia.
A variable population of eosinophils along with lymphoid 
follicles is routinely seen in up to 50% of these cases. One 
distinguishing feature noted in pulmonary cases of IgG4-
RSD is that the arteries are also frequently involved and 
obliterated as opposed to other body sites wherein veins are 
selectively involved.139,140 Endothelialitis characterized by a 
lymphoplasmacytic infiltrate in the subendothelium leading 
to narrowing and obliteration of the vascular lumen is often 
identified. Visceral or parietal pleural involvement is noted 
usually in the form of fibrous thickening accompanied by a 
chronic lymphoplasmacytic infiltrate with or without fibrin-
ous exudates.139-141
Breast
IgG4-related sclerosing mastitis can present as single or mul-
tiple unilateral or bilateral painless masses, with or without 
evidence of systemic IgG4-RSD.70,143 Morphologically, it is 
characterized by a prominent lymphoplasmacytic infiltrates 
with lymphoid follicle formation, patchy fibrosis, and atro-
phy of breast lobules. Phlebitis is also seen in some cases. 
The differential diagnosis includes involvement of the breast 
by lymphoma owing to the dense lymphoplasmacytic infil-
trate or hyaline-vascular variant of Castleman disease if fol-
Noninfectious aortitis is represented by a group of inflam-
matory disorders characterized by chronic inflammation 
within the aortic wall, wherein the evident inflammation is 
not considered to be due to infection.119  Noninfectious aorti-
tis is most commonly seen involving the thoracic aorta, es-
pecially the ascending aorta, and may result from well 
known systemic rheumatologic disorders such as giant cell 
arteritis, Takayasu arteritis, rheumatoid arthritis, ankylosing 
spondylitis, and Behcet’s disease.120,121
The lesions described above are often characterized by a 
variably prominent lymphoplasmacytic infiltrate, sclerosis, 
and phlebitis which are essentially identical to those of 
IgG4-RSD.122 A frequent  association with pancreatitis has 
also been reported in several cases.118,123 Upon extrapolating 
these findings, a significant proportion of cases of retroperi-
toneal fibrosis,124,125 mediastinal fibrosis,67 sclerosing mes-
enteritis,126 periaortitis and inflammatory aortic aneurysm 
(with cases predominantly involving abdominal aorta with 
rare cases involving aortic arch)71,127-132 have been demon-
strated to express markedly increased numbers of IgG4+ 
plasma cells, and hence represent members of IgG4-RSD. 
It has not been determined at present whether the group 
with no significant increase in IgG4+ cells has different eti-
ologies or represents burnt out IgG4- RSD.31
Thyroid
Involvement of the thyroid gland as part of the spectrum of 
IgG4-RSD is being reported increasingly. Patients with AIP 
often have concomitant evidence of hypothyroidism, with 
increased levels of antithyroglobulin antibody.133 The exact 
pathogenetic mechanism for this phenomenon has yet to be 
elucidated. A study by Li, et al.134,135 involved segregating 
70 cases of Hashimoto thyroiditis into 2 groups: 19 IgG4- 
related cases and 51 non-IgG4-related cases. The IgG4-re-
lated group comprised of cases with a greater degree of 
stromal fibrosis, lymphoplasmacytic infiltration, and thy-
roid follicular cell destruction than the other group. The 
IgG4-related subset is associated with a higher level of cir-
culating thyroid autoantibodies, lower female-to-male ratio 
and an aggressive clinical course. It is possible that hypo-
thyroidism in patients with autoimmune pancreatitis may 
result from an IgG4-related thyroiditis which may be mis-
taken for Hashimoto thyroiditis in view of the overlapping 
symptoms and laboratory findings. Riedel thyroiditis is also 
regarded as a component of the multifocal fibrosclerosis 
seen in IgG4-RSD with reports backing this theory based 
on immunohistochemical findings.136-138 IgG4-Related Sclerosing Disease 
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tuitary gland (IgG4-related infundibulo-hypophysitis). A 
male predominance is noted. The clinical picture includes 
patients presenting with hypopituitarism, diabetes insipidus, 
and/or symptomatic local mass effect.151-156
A pituitary mass and/or thickening of the pituitary stalk 
are identified on imaging studies. The treatment modality is 
steroid therapy which usually elicits a favorable response 
and manifests as a marked reduction in lesional size and 
correction of hormonal imbalances.151-156 An accompanying   
meningeal involvement in the form of hypertrophic pachy-
meningitis or sinus involvement, with extension to the sel-
lar and parasellar regions is identified in some cases.152 The   
pituitary shows patchy or extensive interstitial infiltration of 
lymphocytes and plasma cells, along with loss of pituitary 
parenchyma. 
Rare cases of dural spinal involvement have been report-
ed (IgG4-related sclerosing pachymeningitis).157 Such le-
sions described as idiopathic hypertrophic pachymeningitis 
may represent part of the spectrum of IgG4-RSD.158,159 It is 
still unclear whether a few reported cases of  intracranial in-
flammatory pseudotumor with increased IgG4+ plasma 
cells reported by Lui, et al.160 actually represent IgG4-RSD 
since these patients did not exhibit any other manifestations 
of systemic IgG4-RSD.
licles with regressive changes are seen.31
Kidney and urinary tract
IgG4-RSD may also involve the kidneys and urinary tract 
leading to disturbances in renal function.144-147 Radiologic 
studies may demonstrate the presence of poorly circum-
scribed nodular masses in the kidneys, often necessitating 
the exclusion of malignancy.145 The commonest findings on 
biopsy or nephrectomy are tubulointerstitial nephritis with 
an IgG4-positive plasma cell-rich inflammatory infiltrate, 
fibrosis, and tubular atrophy. IgG4 electron-dense deposits 
have been demonstrated in the peritubular basement mem-
brane using electron microscopy. The renal glomeruli are 
usually uninvolved but few cases with concurrent membra-
nous nephropathy have been recorded.144-148 The tubuloint-
erstitial nephritis is steroid responsive, whereas the response 
of membranous glomerulonephritis can be variable. IgG4-
related chronic sclerosing pyelitis and IgG4-associated in-
flammatory pseudotumor of the ureter presenting as hydro-
nephrosis have also been reported (Fig. 4).149,150
Central nervous system
Central nervous system involvement by IgG4-RSD is ex-
tremely rare, and the most commonly reported site is the pi-
Fig. 4. Microscopic features of IgG4-associated inflammatory pseudotumor of ureter. (A) Fibroinflammatory lesion involves the entire ure-
teral wall and extends into periureteral adipose tissue (H&E stain, original magnification ×12.5). (B) Abundant plasma cells are intermixed 
with scattered histiocytes, fibroblasts and collagen fibers (H&E stain, original magnification ×400). (C) Obliterative phlebitis is identified in 
the periureteral adipose tissue (H&E stain, original magnification ×100). (D) A significant subset of plasma cells is positive for IgG4 (immu-
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be multifocal with the commonest nodes involved being 
mediastinal, abdominal, and axillary lymph nodes. Clinical 
manifestations vary greatly.66,161,172 Enlarged asymptomatic 
lymph nodes are identified in surgical resection specimens or 
identified on imaging studies of patients with known IgG4-
RSD. Lymphadenopathy may also develop following an 
established diagnosis of extranodal IgG4-RSD or may be 
the initial presenting manifestation with subsequent discov-
ery of systemic IgG4-RSD. The enlarged lymph nodes may 
be asymptomatic or may give rise to a mass effect in vari-
ous body sites. 
The differential diagnosis in these cases with lymphade-
nopathy includes lymphoma, multicentric Castleman dis-
ease, or metastatic malignant tumor. The lymph nodes are 
usually not exceedingly enlarged (≤2 cm) and not associat-
ed with fever and weight loss. Serum lactate dehydrogenase   
level is normal or only slightly elevated. Other laboratory 
findings include raised serum IgG4, serum IgG, polyclonal 
hypergammaglobulinemia and elevated erythrocyte sedi-
mentation rate (ESR).66,161 
The morphologic features of IgG4-related lymphadenopa-
thy are different from those of extranodal sites since there is 
usually no sclerosis or phlebitis. Five histologic patterns of 
IgG4-related lymphadenopathy have been described.66,79,161 
Skin and other miscellaneous body sites
Skin involvement in IgG4-RSD may be either isolated or as 
part of systemic IgG4-RSD.68,161 The clinical presentation is 
in the form of cutaneous plaques or nodules tending to in-
volve the head and neck. Microscopic examination reveals 
a dermal and subcutaneous nodular lymphoplasmacytic in-
filtrate with formation of lymphoid follicles and dermal or 
subcutaneous sclerosis. A markedly increased number of 
IgG4+ plasma cells, small lymphocytes, and variable infil-
trate of eosinophils is identified.31
Cases of IgG4-RSD have been reported in the pericardi-
um,162 prostate,163 seminal vesicles,164 nose, paranasal sinus-
es165,166 and uterine cervix (idiopathic cervical fibrosis).167 
Questionable entities currently include autoimmune esoph-
agitis and splenic sclerosing angiomatoid nodular transfor-
mation, which exhibit some of the features overlapping with 
IgG4-RSD, including increased plasma cells and sclero-
sis.168-171 However, there is no definite evidence to currently 
include these lesions under the spectrum of IgG4-RSD.
Lymph nodes
Lymphadenopathy is identified in up to 80% of patients with 
autoimmune (IgG4-related sclerosing) pancreatitis as evi-
denced by imaging studies.62 Lymph node involvement may 
Fig. 5. Microscopic features of IgG4-related lymphadenopathy, type I. (A) Multicentric Castleman disease-like pattern with interfolicular 
expansion (H&E stain, ×40). (B) Perivascular  sclerosis and hyalinized venules in lymphoid follicles are identified (H&E stain, ×100). (C) The   
interfollicular area is infiltrated by plasma cells intermixed with collagen fibers (H&E stain, ×400). (D) Many plasma cells are positive for 
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mune disease.189 An association of IgG4-related AIP with 
gastric ulcer and Helicobacter pylori (H. pylori) infection has 
been proposed.190-192 It has been theorized by Okazaki, et 
al.193  that the development of the acronym ‘AIP’ involves a 
biphasic mechanism in which the initial response to self-anti-
gens such as carbonic anhydrase, lactoferrin, pancreatic se-
cretory trypsin inhibitor and ά-fodrin and molecular mimicry 
(H. pylori) are induced by decreased naive regulatory T cells, 
in conjunction with T-helper 1 cells releasing proinflammato-
ry cytokines. Progression is mediated through increased 
memory regulatory T cell and T-helper 2 cell immune re-
sponses resulting in chronic inflammation. The inflammatory 
infiltrate usually comprises of a mixed population of T and B 
cells, with increased CD4+, CD25+, FOXP3+ regulatory T 
cells.31,194,195 T-helper cell 2 cytokines (interleukin-4, interleu-
kin-5, and interleukin-13) and regulatory cytokines (interleu-
kin-10 and transforming growth factor) are upregulated in 
the involved tissues.194-196 Other proposed hypothesis regard-
ing the pathogenesis include enhanced T-helper type 2 re-
sponses to intestinal microflora197 and an immune-mediated 
pathogenesis based on the ultrastructural finding of electron 
dense immune complex deposits along the basement mem-
branes of pancreatic acini and renal tubules.32 
According to the results of a recent study conducted by 
screening of pooled IgG from patients with AIP, a specific 
reactivity with a peptide demonstrating homology with 
plasminogen-binding protein of H. pylori and with ubiqui-
tin-protein ligase E3 component n-recognin 2 (an enzyme 
with high levels of expression in pancreatic acinar cells) was 
noted in the serum samples from 90% of patients with AIP 
and 10% of patients with pancreatic cancer. Healthy con-
trols did not show any expression.198 It remains to be seen 
whether H. pylori truly plays a role in the development of 
AIP and IgG4-RSD.
DIAGNOSTIC CRITERIA FOR IgG4-
RELATED SCLEROSING DISEASE
 
Diagnosis of IgG4-RSD requires not only an increase in the 
absolute number of IgG4+ cells but also an increased IgG4+/
IgG+ ratio for the correct diagnosis. An absolute IgG4+ plas-
ma cell count is not sufficient as a sole index as IgG4+ cells 
normally comprise approximately 5% of all IgG+ cells, and 
may be present in significant numbers in any inflammatory 
lesions with increased plasma cells even though the percent-
age might remain in the acceptable range. A high IgG4+/
The various subtypes are as follows: multicentric Castle-
man disease-like pattern (type I),172-178 follicular hyperplasia 
pattern (type II),66 interfollicular plasmacytosis and immu-
noblastosis pattern (type III),66,79,161 progressive transforma-
tion of germinal center-like pattern (type IV),79,179 and nodal 
inflammatory pseudotumor-like pattern (type V).79,179,180 
Abundant IgG4+ polyclonal plasma cells are present in in-
terfollicular and follicle center compartments in all of these 
patterns (Fig. 5).79
IgG4-RELATED SCLEROSING  
DISEASE AND ASSOCIATED 
MALIGNANCIES
Sato, et al.79 have reported cases of ocular marginal zone 
lymphoma associated with ocular adnexal IgG4-related 
sclerosing disease. A few cases of localized non-Hodgkin’s 
lymphoma (marginal zone lymphoma and follicular lympho-
ma) arising in a background of IgG4-related chronic scle-
rosing dacryoadenitis have been recently reported.181 A rare 
example of composite marginal zone lymphoma and classi-
cal Hodgkin lymphoma associated with IgG4-related scle-
rosing disease of the cervical soft tissue has also been pub-
lished.167 A recent study from the Mayo Clinic cites 3 cases 
of lymphoma (2 large B-cell lymphomas and 1 B-cell lym-
phoma unspecified) discovered on follow-up of 111 patients 
with IgG4-related sclerosing disease, suggesting that the 
syndrome increases the risk of developing lymphoma in 
various  body sites.182
Several cases of pancreatic ductal adenocarcinoma have 
been published in association with IgG4-RSD.183-186 Case 
reports of pulmonary adenocarcinoma, salivary duct carci-
noma, urothelial carcinoma in situ and gastrointestinal clear 
cell sarcoma in association with IgG4-RSD have been re-
ported in the lung, parotid gland, ureter and small intestine, 
respectively.140,150,187,188 Further studies are mandated in this 
field to determine if there is any causal relationship be-
tween the malignancies and IgG4-RSD.
PROPOSED ETIOPATHOGENESIS OF 
IgG4-RELATED SCLEROSING DISEASE
The pathogenesis of IgG4-related sclerosing disease is still 
not clearly understood. The disease may represent a hyper-
sensitive/allergic reaction as compared to being an autoim-Mukul Divatia, et al.
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